TrialJCO oncology practice2022

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Nitya Raj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.